Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
|Slideshows|April 14, 2017
6 Key Questions When You Suspect Melancholia
Author(s)Gordon Parker, MD, PhD, DSc, FRANZCP
Most depressed people acknowledge impaired concentration and other related symptoms-but skilled clinicians can distinguish between non-melancholic depression and melancholia. How? They ask the right questions.
Advertisement
View the slides in PDF format.
Advertisement
Related to this article
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
4
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
5